Cochrane · systematic review · CD000478
Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis
Timmer, A, Patton, PH, Chande, N, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
11
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 10 · 90.9%Low 1 · 9.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsAzathioprine versus placebo for maintenance of remission in ulcerative colitis
Population: Patients with quiescent ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to maintain remission Azathioprine vs placebo | RR 0.68 [0.54, 0.86] | 4 studies · 232 participants | Low Downgraded: risk of bias, imprecision |
Any adverse events Azathioprine vs placebo | RR 2.51 [0.82, 7.74] | 4 studies · 232 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawal due to adverse event Azathioprine vs placebo | RR 7 [0.38, 128.87] | 3 studies · 152 participants | Very low Downgraded: risk of bias, imprecision |
Azathioprine versus sulfasalazine for maintenance of remission in ulcerative colitis
Population: Patients with quiescent ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to maintain remission Azathioprine vs sulfasalazine | RR 1.52 [0.66, 3.5] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
6‐Mercaptopurine versus 5‐ASA for maintenance of remission in ulcerative colitis
Population: Patients with quiescent ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to maintain remission 6‐Mercaptopurine vs 5‐ASA | RR 0.53 [0.31, 0.9] | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
6‐Mercaptopurine versus methotrexate for maintenance of remission in ulcerative colitis
Population: Patients with quiescent ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to maintain remission 6‐Mercaptopurine vs methotrexate | RR 0.55 [0.31, 0.95] | 1 study · 26 participants | Very low Downgraded: risk of bias, imprecision |
Azathioprine (AZA) versus cyclosporin of remission in ulcerative colitis
Population: Patients with quiescent ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to maintain remission Azathioprine (AZA) vs cyclosporin of remission | RR 0.8 [0.33, 1.92] | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events across placebo‐controlled and aminosalicylate‐comparator trials
Population: Patients with quiescent ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Any adverse event | RR 2.82 [0.99, 8.01] | 5 studies · 257 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawal due to adverse event | RR 5.43 [1.02, 28.75] | 5 studies · 199 participants | Very low Downgraded: risk of bias, imprecision |
Acute pancreatitis | RR 4.13 [0.48, 35.48] | 6 studies · 279 participants | Very low Downgraded: risk of bias, imprecision |
Bone marrow suppression | RR 3.09 [0.64, 14.83] | 5 studies · 257 participants | Very low Downgraded: risk of bias, imprecision |